Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: PS-341, doxorubicin
Sponsor: University of Wisconsin, Madison
Collaborators: National Cancer Institute (NCI)|Millennium Pharmaceuticals, Inc.